Asenapine maleate | CAS#85650-56-2 | 65576-45-6 | 1412458-61-7

Asenapine maleate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326708

CAS#: 85650-56-2 (maleate)

Description: Asenapine, also known as Org 5222 and HSDB 8061, is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. FDA approved this drug in August 2009.

Chemical Structure

Asenapine maleate

CAS# 85650-56-2 (maleate)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 326708
Name: Asenapine maleate
CAS#: 85650-56-2 (maleate)
Chemical Formula: C21H20ClNO5
Exact Mass: 0.00
Molecular Weight: 401.843
Elemental Analysis: C, 62.77; H, 5.02; Cl, 8.82; N, 3.49; O, 19.91

Price and Availability

Size	Price	Availability
100mg	USD 150	Ready to ship
200mg	USD 250	Ready to ship
500mg	USD 550	Ready to ship
1g	USD 950	Ready to ship
2g	USD 1650	Ready to ship
5g	USD 2950	Ready to ship
10g	USD 3950	Ready to ship
50g	USD 7850	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 85650-56-2 (maleate) 65576-45-6 (free)

Synonym: Org 5222; Org5222; Org-5222; HSDB 8061; HSDB-8061; HSDB8061; Asenapine; Asenapine maleate; trade names Saphris and Sycrest.

IUPAC/Chemical Name: (3aS,12bS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole maleate

InChi Key: GMDCDXMAFMEDAG-CHHFXETESA-N

InChi Code: InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1

SMILES Code: CN1C[C@@](C2=CC=CC=C2OC3=CC=C(Cl)C=C34)([H])[C@]4([H])C1.O=C(O)/C=C\C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related: 85650-56-2 ( Asenapine maleate) 65576-45-6 ( Asenapine free) 1412458-61-7 ( Asenapine HCl).

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#A20T05K11

QC Data:

View QC data: current batch, Lot#A20T05K11

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	Asenapine maleate is a 5-HT (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and D2 antagonist with Ki values of 0.03-4.0 nM, 1.3nM, respectively, and an antipsychotic.
In vitro activity:	To further determine whether AM (Asenapine maleate) act through ROS mediated signaling pathway, CFs were pretreated with or without AM followed by Ang II stimulation. The results demonstrated that AM could reduce the levels of ROS induced by Ang II (Fig. 4A). After pretreatment with 10 μM AM, the Ang II-induced activation of the TGFβ1/MAPK signal pathway was suppressed. Treatment with AM also reduced the expression of TGFβ1 and decreased the phosphorylation levels of ERK, JNK, and p38MAPK. Therefore, this study confirmed that AM can inhibit Ang II-induced cardiac fibrosis through the ROS/TGFβ1/MAPK signaling pathway (Fig. 4B and C). Reference: Biochem Biophys Res Commun. 2021 May 14;553:172-179. https://pubmed.ncbi.nlm.nih.gov/33773140/
In vivo activity:	As expected, administration of cumulative doses of the 5‐HT7 agonist LP‐44 (1‐4 mg/kg, i.v.) in control rats induced a dose‐dependent decrease in the firing activity of DR 5‐HT neurons with ED50=1.45 mg/kg (n=7; Figure 3A,B). Two‐way repeated‐measures ANOVA revealed a significant effect of SB 269970 pretreatment (F1,40=6.98, P<.05) on the potency of LP‐44 (F4,40=54.13, P<.001), but no SB 269970 x LP‐44 interaction. Similarly, an injection of Asenapine (1 mg/kg, i.v.) reduced the suppressant effect of LP‐44 on the firing activity of DR 5‐HT neurons, with ED50=3.54 mg/kg (n=7, Figure 3C,D). Two‐way repeated‐measures ANOVA indicated a significant effect of Asenapine (F1,55= 0.17, P<.01) on the potency of LP‐44 (F5,55=61.90, P<.001), and a significant interaction effect (F5,55=5.38, P<.001). Reference: CNS Neurosci Ther. 2017 Jun; 23(6): 518–525. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492759/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	48.4	120.42
	Ethanol	20.1	49.99
	Water	6.3	15.55

Preparing Stock Solutions

The following data is based on the product molecular weight 401.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Wu HH, Meng TT, Chen JM, Meng FL, Wang SY, Liu RH, Chen JN, Ning B, Li Y, Su GH. Asenapine maleate inhibits angiotensin II-induced proliferation and activation of cardiac fibroblasts via the ROS/TGFβ1/MAPK signaling pathway. Biochem Biophys Res Commun. 2021 May 14;553:172-179. doi: 10.1016/j.bbrc.2021.03.042. Epub 2021 Mar 24. PMID: 33773140. 2. Grossini E, Gramaglia C, Farruggio S, Camillo L, Mary D, Vacca G, Zeppegno P. Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts. J Pharmacol Pharmacother. 2016 Jan-Mar;7(1):6-14. doi: 10.4103/0976-500X.179358. PMID: 27127388; PMCID: PMC4831496. 3. Foute Nelong T, Manduca JD, Zonneveld PM, Perreault ML. Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. Neurosci Lett. 2019 Oct 15;711:134404. doi: 10.1016/j.neulet.2019.134404. Epub 2019 Jul 26. PMID: 31356843. 4. Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N. Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission. CNS Neurosci Ther. 2017 Jun;23(6):518-525. doi: 10.1111/cns.12698. Epub 2017 Apr 17. PMID: 28417559; PMCID: PMC6492759.
In vitro protocol:	1. Wu HH, Meng TT, Chen JM, Meng FL, Wang SY, Liu RH, Chen JN, Ning B, Li Y, Su GH. Asenapine maleate inhibits angiotensin II-induced proliferation and activation of cardiac fibroblasts via the ROS/TGFβ1/MAPK signaling pathway. Biochem Biophys Res Commun. 2021 May 14;553:172-179. doi: 10.1016/j.bbrc.2021.03.042. Epub 2021 Mar 24. PMID: 33773140. 2. Grossini E, Gramaglia C, Farruggio S, Camillo L, Mary D, Vacca G, Zeppegno P. Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts. J Pharmacol Pharmacother. 2016 Jan-Mar;7(1):6-14. doi: 10.4103/0976-500X.179358. PMID: 27127388; PMCID: PMC4831496.
In vivo protocol:	1. Foute Nelong T, Manduca JD, Zonneveld PM, Perreault ML. Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. Neurosci Lett. 2019 Oct 15;711:134404. doi: 10.1016/j.neulet.2019.134404. Epub 2019 Jul 26. PMID: 31356843. 2. Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N. Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission. CNS Neurosci Ther. 2017 Jun;23(6):518-525. doi: 10.1111/cns.12698. Epub 2017 Apr 17. PMID: 28417559; PMCID: PMC6492759.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Scheidemantel T, Korobkova I, Rej S, Sajatovic M. Asenapine for bipolar disorder. Neuropsychiatr Dis Treat. 2015 Dec 4;11:3007-17. doi: 10.2147/NDT.S78043. eCollection 2015. Review. PubMed PMID: 26674884; PubMed Central PMCID: PMC4675633.

2: Hay A, Byers A, Sereno M, Basra MK, Dutta S. Asenapine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Nov 24;(11):CD011458. doi: 10.1002/14651858.CD011458.pub2. Review. PubMed PMID: 26599405.

3: Dell'Osso B, Cremaschi L, Palazzo MC, Spagnolin G, Cattaneo A, Grancini B, Maggi M, Altamura AC. Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series. Expert Opin Drug Saf. 2014 Sep;13(9):1199-208. doi: 10.1517/14740338.2014.938047. Epub 2014 Aug 1. Review. PubMed PMID: 25084462.

4: Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903. doi: 10.1517/17425255.2014.908185. Epub 2014 May 3. Review. PubMed PMID: 24793403.

5: Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014 Jun;13(6):803-30. doi: 10.1517/14740338.2014.908183. Epub 2014 May 3. Review. PubMed PMID: 24793161.

6: Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013 Nov-Dec;36(6):223-38. doi: 10.1097/WNF.0b013e3182aa38c4. Review. PubMed PMID: 24201235.

7: Cortese L, Bressan RA, Castle DJ, Mosolov SN. Management of schizophrenia: clinical experience with asenapine. J Psychopharmacol. 2013 Apr;27(4 Suppl):14-22. doi: 10.1177/1359786813482533. Epub 2013 Mar 27. Review. PubMed PMID: 23535351.

8: Young AH, Altamura AC, González-Pinto AM, Millet B, Wiedemann K. Use of asenapine in clinical practice for the management of bipolar mania. J Psychopharmacol. 2013 Apr;27(4 Suppl):3-13. doi: 10.1177/1359786813482534. Epub 2013 Mar 27. Review. PubMed PMID: 23535350.

9: Fagiolini A, Forgione RN, Morana B, Maccari M, Goracci A, Bossini L, Pellegrini F, Cuomo A, Casamassima F. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. doi: 10.1517/14656566.2013.765859. Epub 2013 Jan 29. Review. PubMed PMID: 23356509.

10: Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. Review. PubMed PMID: 23272794.

11: Asenapine: a less effective, yet, more dangerous neuroleptic! Prescrire Int. 2012 Oct;21(131):229-32. Review. PubMed PMID: 23185842.

12: Tarazi FI, Neill JC. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov. 2013 Jan;8(1):93-103. doi: 10.1517/17460441.2013.738193. Epub 2012 Nov 4. Review. PubMed PMID: 23121334.

13: De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review. PubMed PMID: 22900950.

14: Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. Review. PubMed PMID: 22849428.

15: Samalin L, Tixeront C, Llorca PM. [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice]. Encephale. 2012 Jun;38(3):257-65. doi: 10.1016/j.encep.2012.05.001. Epub 2012 Jun 5. Review. French. Erratum in: Encephale. 2012 Oct;38(5):448-9. PubMed PMID: 22726414.

16: Stoner SC, Pace HA. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther. 2012 May;34(5):1023-40. doi: 10.1016/j.clinthera.2012.03.002. Epub 2012 Apr 10. Review. PubMed PMID: 22494521.

17: Potkin SG. Asenapine: a clinical overview. J Clin Psychiatry. 2011;72 Suppl 1:14-8. doi: 10.4088/JCP.10075su1.03. Review. PubMed PMID: 22217438.

18: McIntyre RS, Wong R. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. Clin Schizophr Relat Psychoses. 2012 Jan;5(4):217-20. doi: 10.3371/CSRP.5.4.6. Review. PubMed PMID: 22182459.

19: Pompili M, Serafini G, Innamorati M, Ambrosi E, Telesforo L, Venturini P, Giordano G, Battuello M, Lester D, Girardi P. Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? Expert Rev Neurother. 2011 Jul;11(7):989-1006. doi: 10.1586/ern.11.82. Review. PubMed PMID: 21721916.

20: Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011 Mar;123(2):153-62. doi: 10.3810/pgm.2011.03.2273. Review. PubMed PMID: 21474903.

Your view history

Asenapine maleate featured